Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials-Reference-Cited by-同舟云学术

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials

Published:2021-01 Issue:10268 Volume:397 Page:27-38
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sáez-Llorens Xavier,Bandyopadhyay Ananda S,Gast Christopher,Leon Tirza De,DeAntonio Rodrigo,Jimeno Jose,Caballero Maria Isabel,Aguirre Gabriela,Oberste M Steven,Weldon William C,Konopka-Anstadt Jennifer L,Modlin John,Bachtiar Novilia S,Fix Alan,Konz John,Clemens Ralf,Costa Clemens Sue Ann,Rüttimann Ricardo

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Meeting of the strategic advisory group of experts on immunization, 31 March–1 April 2020: conclusions and recommendations: polio;Wkly Epidemiol Rec,2020

2. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain;Kalkowska;Risk Anal,2020

3. Vaccine-derived polioviruses;Burns;J Infect Dis,2014

4. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019–February 2020;Alleman;MMWR Morb Mortal Wkly Rep,2020

5. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016;Hampton;MMWR Morb Mortal Wkly Rep,2016

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children;2024-01-30

2. Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?;Frontiers in Public Health;2024-01-08

3. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study;The Lancet Infectious Diseases;2024-01

4. Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study;The Lancet Infectious Diseases;2024-01

5. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic;The Lancet Infectious Diseases;2023-12